Press Releases

All Releases
View Summary Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
02/03/15
PDF 22.5 KB Add to Briefcase
View Summary MannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan Edstrom Appointed to CEO
01/12/15
PDF 12.3 KB Add to Briefcase
View Summary MannKind Earns $50 Million in Milestone Payments From Sanofi
01/08/15
PDF 7.6 KB Add to Briefcase
View Summary MannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference
01/07/15
PDF 8.4 KB Add to Briefcase
View Summary MannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference
11/25/14
PDF 8.4 KB Add to Briefcase
View Summary MannKind Corporation Reports 2014 Third Quarter Financial Results
11/03/14
PDF 18.1 KB Add to Briefcase
View Summary MannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call on November 3, 2014
10/27/14
PDF 8.7 KB Add to Briefcase
View Summary MannKind Announces Receipt of $150 Million Licensing Upfront Payment
09/29/14
PDF 7.7 KB Add to Briefcase
View Summary MannKind Announces Closing of Global Licensing Agreement With Sanofi
09/24/14
PDF 8.7 KB Add to Briefcase
View Summary MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
09/02/14
PDF 8.2 KB Add to Briefcase
View Summary Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin
08/11/14
PDF 18.0 KB Add to Briefcase
View Summary MannKind Corporation Reports 2014 Second Quarter Financial Results
08/11/14
PDF 18.0 KB Add to Briefcase
View Summary MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
08/05/14
PDF 8.6 KB Add to Briefcase
View Summary MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
06/27/14
PDF 14.9 KB Add to Briefcase
View Summary MannKind to Present at Upcoming Conferences
05/27/14
PDF 8.6 KB Add to Briefcase
View Summary MannKind Corporation Reports 2014 First Quarter Financial Results
05/12/14
PDF 15.8 KB Add to Briefcase
View Summary MannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference
05/07/14
PDF 8.3 KB Add to Briefcase
View Summary MannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014
05/05/14
PDF 8.7 KB Add to Briefcase
View Summary MannKind Updates Status of New Drug Application for AFREZZA(R)
04/07/14
PDF 8.9 KB Add to Briefcase
View Summary FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
04/01/14
PDF 10.4 KB Add to Briefcase
Showing 81-100 of 305 Page: 1 2 3 4 5 6 7 8 9 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

MNKD

Exchange:
NASDAQ GM and TASE(US Dollar)

Price: 1.43

Change: 0.01 (0.704%)

Volume: 530,425

Data as of
08/23/2017 04:00 PM ET .
Minimum 20 minute delay.

Refresh Quote >

Locations

Learn more about MannKind's offices in the United States

Learn More